Thalia Therapeutics Plc (FRA:0GO)

Germany · Delayed Price · Currency is EUR

0.0050

0.00 (0.00%)

Last updated: Jun 26, 2026, 9:08 AM CET

400.00% (1Y)

Market Cap	6.27M +42.7%
Revenue (ttm)	8.33K -0.2%
Net Income	-1.38M
EPS	-0.00
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.0050
Previous Close	0.0050
Day's Range	0.0050 - 0.0050
52-Week Range	0.0005 - 0.0265
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 2, 2026

About Thalia Therapeutics

Thalia Therapeutics Plc, a specialist pharmaceutical company, develops nanoparticle silica delivery systems to enhance the cellular delivery and potency of cancer treatments and vaccines in the United Kingdom. It develops Nuvec, a silica nanoparticle delivery system, which has an irregular surface structure that traps and protects siRNA/RNA/DNA; and Liptide, a platform to deliver a proprietary siRNA sequence to silence a fibrotic gene. The company also engages in the development of N4 101, an orally delivered inflammation inhibitor which is in ... [Read more]

Industry In Vitro and In Vivo Diagnostic Substances

Founded 1979

Employees 4

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol 0GO

Financial Performance

In 2025, Thalia Therapeutics's revenue was 7,264, a decrease of -0.25% compared to the previous year's 7,282. Losses were -1.21 million, 13.8% more than in 2024.

Financial numbers in GBP Financial Statements